Abstract
Temperature-sensitive transient receptor potential (TRP) channels such as TRPA1 and TRPV1 have been identified as downstream ion channel targets in the transduction of itch. As a member of the temperature-sensitive TRP family, the Ca2+-permeable nonselective cation channel TRPV3 is expressed abundantly in skin keratinocytes. Recent identification of gain-of-function mutations of human TRPV3 from patients with Olmsted syndrome, which is characterized by severe itching and palmoplantar and periorificial keratoderma, unveils its crucial role in chronic itch and skin diseases. In this review, we will focus on recent progress made in the understanding of TRPV3 that emerges as an attractive target for developing effective antipruritic therapy for chronic itch or skin-related diseases.
Footnotes
- Received December 20, 2016.
- Accepted March 31, 2017.
This research was supported by the National Natural Sciences Foundation of China [Grant 81573410 (to K.W.)], the Ministry of Science and Technology of China [Grant 2014ZX09507003-006-004 (to K.W.)], and the Natural Sciences Foundation of Shandong Province [Grant ZR2015QL008 (to K.W.)].
- Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|